Normalization of postinfarct biomechanics using a novel tissue-engineered angiogenic construct.

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Cardiovascular Research

Background:

• Cell-mediated angiogenic therapy for ischemic heart disease faces challenges like cell death and dispersion.
• A novel tissue-engineered approach using extracellular matrix scaffolds with endothelial progenitor cells (EPCs) is proposed.
• This method aims to overcome limitations by providing a supportive environment for cell survival and effective myocardial delivery.

Purpose of the Study:

• To develop and evaluate a tissue-engineered construct for treating ischemic heart disease.
• To assess the ability of endothelial progenitor cells (EPCs) seeded on a collagen/vitronectin matrix to promote angiogenesis.
• To determine if this construct can restore normal biomechanical properties to infarcted myocardium.

Main Methods:

• Endothelial progenitor cells (EPCs) were isolated and cultured.
• EPCs were seeded onto a collagen/vitronectin matrix and modified with stromal cell-derived factor-1α.
• The engineered construct was implanted onto the myocardium in a rat model of acute myocardial infarction.

Main Results:

• In vitro studies showed a significant increase in vasculogenesis (8 vs. 0 vessels/hpf).
• Post-implantation, EPCs migrated from the construct to the myocardium, indicating an angiogenic effect.
• Myocardial elasticity normalized after implantation of the tissue-engineered construct (239 kPa vs. infarct 304 kPa).

Conclusions:

• A tissue-engineered EPC construct effectively restores and normalizes ventricular biomechanics after myocardial infarction.
• This approach offers a promising strategy for treating ischemic heart disease by enhancing cell survival and therapeutic delivery.